ADORA2A and metabolic syndrome: Patients with dyslipidemia showed a reduction in myocardial blood flow and reduced coronary artery dilation upon intravenous administration of adenosine and, because A2AR is implicated in coronary artery dilation, it has been suggested that its expression or function may be impacted in dyslipidemia [48].